Your browser doesn't support javascript.
loading
How to use the Harmonising Outcome Measures for Eczema Core Outcome Set for atopic dermatitis trials: a users' guide.
Thomas, Kim S; Howells, Laura; Leshem, Yael A; Simpson, Eric L; Apfelbacher, Christian; Spuls, Phyllis I; Gerbens, Louise A A; Jacobson, Michael E; Katoh, Norito; Williams, Hywel C; Stuart, Beth L.
Afiliação
  • Thomas KS; Centre of Evidence Based Dermatology, School of Medicine, University of Nottingham, Nottingham, UK.
  • Howells L; Centre of Evidence Based Dermatology, School of Medicine, University of Nottingham, Nottingham, UK.
  • Leshem YA; Division of Dermatology, Rabin Medical Center, Petach-Tikva, Israel.
  • Simpson EL; School of Medicine, Tel-Aviv University, Tel-Aviv, Israel.
  • Apfelbacher C; Department of Dermatology, Oregon Health and Science University, Portland, OR, USA.
  • Spuls PI; Institute of Social Medicine and Health Systems Research, Otto von Guericke University Magdeburg, Magdeburg, Germany.
  • Gerbens LAA; Lee Kong Chian School of Medicine, Nanyang Technological University Singapore, Singapore.
  • Jacobson ME; Department of Dermatology, Amsterdam UMC, location Academic Medical Center, University of Amsterdam, Amsterdam Public Health, Infection and Immunity, Amsterdam, the Netherlands.
  • Katoh N; Department of Dermatology, Amsterdam UMC, location Academic Medical Center, University of Amsterdam, Amsterdam Public Health, Infection and Immunity, Amsterdam, the Netherlands.
  • Williams HC; Department of Dermatology, Oregon Health and Science University, Portland, OR, USA.
  • Stuart BL; Department of Dermatology, Kyoto Prefectural University of Medicine, Kyoto, Japan.
Br J Dermatol ; 190(4): 527-535, 2024 Mar 15.
Article em En | MEDLINE | ID: mdl-38123134
ABSTRACT

BACKGROUND:

The Harmonising Outcome Measures for Eczema (HOME) initiative has agreed upon the Core Outcome Set (COS) for use in atopic dermatitis (AD) clinical trials, but additional guidance is needed to maximize its uptake.

OBJECTIVES:

To provide answers to some of the commonly asked questions about using the HOME COS; to provide data to help with the interpretation of trial results; and to support sample size calculations for future trials. METHODS AND

RESULTS:

We provide practical guidance on the use of the HOME COS for investigators planning clinical trials in patients with AD. It answers some of the common questions about using the HOME COS, how to access the outcome measurement instruments, what training/resources are needed to use them appropriately and clarifies when the COS is applicable. We also provide exemplar data to inform sample size calculations for eczema trials and encourage standardized data collection and reporting of the COS.

CONCLUSIONS:

By encouraging adoption of the COS and facilitating consistent reporting of outcome data, it is hoped that the results of eczema trials will be more comprehensive and readily combined in meta-analyses and that patient care will subsequently be improved.
Assuntos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Dermatite Atópica / Eczema Limite: Humans Idioma: En Revista: Br J Dermatol Ano de publicação: 2024 Tipo de documento: Article País de afiliação: Reino Unido

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Dermatite Atópica / Eczema Limite: Humans Idioma: En Revista: Br J Dermatol Ano de publicação: 2024 Tipo de documento: Article País de afiliação: Reino Unido